Deirdre K Tobias, Alisa K Manning, Jennifer Wessel, Sridharan Raghavan, Kenneth E Westerman, Alexander G Bick, Daniel Dicorpo, Eric A Whitsel, Jason Collins, Adolfo Correa, L Adrienne Cupples, Josée Dupuis, Mark O Goodarzi, Xiuqing Guo, Barbara Howard, Leslie A Lange, Simin Liu, Laura M Raffield, Alex P Reiner, Stephen S Rich, Kent D Taylor, Lesley Tinker, James G Wilson, Peitao Wu, April P Carson, Ramachandran S Vasan, Myriam Fornage, Bruce M Psaty, Charles Kooperberg, Jerome I Rotter, James Meigs, JoAnn E Manson
OBJECTIVE: Clonal hematopoiesis of indeterminate potential (CHIP) is an aging-related accumulation of somatic mutations in hematopoietic stem cells, leading to clonal expansion. CHIP presence has been implicated in atherosclerotic coronary heart disease (CHD) and all-cause mortality, but its association with incident type 2 diabetes (T2D) is unknown. We hypothesized that CHIP is associated with elevated risk of T2D. RESEARCH DESIGN AND METHODS: CHIP was derived from whole-genome sequencing of blood DNA in the National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine (TOPMed) prospective cohorts...
September 27, 2023: Diabetes Care
Naveed Sattar, Shahrad Taheri, David P Astling, Jessica Chadwick, Michael A Hinterberg, Michael V Holmes, Emma V Troth, Paul Welsh, Hadeel Zaghloul, Odette Chagoury, Mike Lean, Roy Taylor, Steve Williams
OBJECTIVE: To determine the extent to which changes in plasma proteins, previously predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials. RESEARCH DESIGN AND METHODS: We applied SomaSignal predictive tests (each derived from ∼5,000 plasma protein measurements using aptamer-based proteomics assay) to baseline and 1-year samples of trial intervention (Diabetes Remission Clinical Trial [DiRECT], n = 118, and Diabetes Intervention Accentuating Diet and Enhancing Metabolism [DIADEM-I], n = 66) and control (DiRECT, n = 144, DIADEM-I, n = 76) group participants...
September 26, 2023: Diabetes Care
Priscilla A Hollander, Heidi Krause-Steinrauf, Nicole M Butera, Erin J Kazemi, Andrew J Ahmann, Basma N Fattaleh, Mary L Johnson, Tina Killean, Violet S Lagari, Mary E Larkin, Elizabeth A Legowski, Neda Rasouli, Holly J Willis, Catherine L Martin
OBJECTIVE: To describe rescue insulin use and associated factors in the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: GRADE participants (type 2 diabetes duration <10 years, baseline A1C 6.8%-8.5% on metformin monotherapy, N = 5,047) were randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin and followed quarterly for a mean of 5 years. Rescue insulin (glargine or aspart) was to be started within 6 weeks of A1C >7...
September 26, 2023: Diabetes Care
Raffael Ott, Robert Stein, Helena H Hauta-Alus, Justiina Ronkainen, Sílvia Fernández-Barrés, Ulrike Spielau, Holger Kirsten, Tanja Poulain, Phillip E Melton, Leanne K Küpers, Hatim Azaryah, Marco Colombo, Kathrin Landgraf, Elmar W Tobi, Therese O'Sullivan, Rae-Chi Huang, Cristina Campoy, Christiane Winkler, Jesus Vioque, Martine Vrijheid, Wieland Kiess, Antje Körner, Sylvain Sebert, Marjo-Riitta Jarvelin, Anette-G Ziegler, Sandra Hummel
OBJECTIVE: Dietary glycemic index (GI) and glycemic load (GL) are associated with cardiometabolic health in children and adolescents, with potential distinct effects in people with increased BMI. DNA methylation (DNAm) may mediate these effects. Thus, we conducted meta-analyses of epigenome-wide association studies (EWAS) between dietary GI and GL and blood DNAm of children and adolescents. RESEARCH DESIGN AND METHODS: We calculated dietary GI and GL and performed EWAS in children and adolescents (age range: 4...
September 26, 2023: Diabetes Care
Connor Drake, Jorge Morales Alfaro, Dan V Blalock, Kristin Ito, Bryan C Batch, Hayden B Bosworth, Seth A Berkowitz, Leah L Zullig
OBJECTIVE: To evaluate the relationship between social needs and metformin use among adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In a prospective cohort study of adults with T2D (n = 722), we linked electronic health record (EHR) and Surescripts (Surescripts, LLC) prescription network data to abstract data on patient-reported social needs and to calculate metformin adherence based on expected refill frequency using a proportion of days covered methodology...
September 26, 2023: Diabetes Care
Hsin-Fang Chung, Annette J Dobson, Kunihiko Hayashi, Rebecca Hardy, Diana Kuh, Debra J Anderson, Yvonne T van der Schouw, Darren C Greenwood, Janet E Cade, Panayotes Demakakos, Eric J Brunner, Sophie V Eastwood, Sven Sandin, Elisabete Weiderpass, Gita D Mishra
OBJECTIVE: To investigate associations between age at natural menopause, particularly premature ovarian insufficiency (POI; natural menopause before age 40 years), and incident type 2 diabetes (T2D) and identify any variations by ethnicity. RESEARCH DESIGN AND METHODS: We pooled individual-level data of 338,059 women from 13 cohort studies without T2D before menopause from six ethnic groups: White (n = 177,674), Chinese (n = 146,008), Japanese (n = 9,061), South/Southeast Asian (n = 2,228), Black (n = 1,838), and mixed/other (n = 1,250)...
September 26, 2023: Diabetes Care
Maria Stepanova, Ameeta Kumar, Pamela Brandt, Nagashree Gundurao, Kenneth Cusi, Saleh Al Qahtani, Zobair M Younossi
OBJECTIVE: Type 2 diabetes (T2D) is a major driver of chronic diseases around the globe. The aim was to assess the impact of T2D on the outcomes of solid organ transplantations. RESEARCH DESIGN AND METHODS: We used the Scientific Registry of Transplant Recipients from 2006 to 2021 to collect data for all patients age ≥18 years who received a lung, heart, liver, or kidney transplant in the U.S. RESULTS: We included 462,692 solid organ transplant recipients: 31,503 lung, 38,004 heart, 106,639 liver, and 286,440 kidney transplantations...
September 25, 2023: Diabetes Care
Rose Mckeon Olson, Cody P Nolan, Neha Limaye, Miriam Osei, Daniel Palazuelos
OBJECTIVE: To quantify the prevalence of diabetes and barriers to care among U.S. migrant farmworkers (i.e. those who travel from their permanent residence for seasonal farmwork). RESEARCH DESIGN AND METHODS: Age-adjusted prevalence of self-reported diabetes and barriers to care were calculated among adult U.S. farmworkers from 2008 to 2017 National Agricultural Workers Surveys. RESULTS: Among 16,913 farmworkers, 30.7% reported one or more barriers to care, most often due to cost...
September 22, 2023: Diabetes Care
Qian Xiao, John Durbin, Cici Bauer, Chris Ho Ching Yeung, Mariana G Figueiro
OBJECTIVE: The alignment between environmental stimuli (e.g., dark, light) and behavior cycles (e.g., rest, activity) is an essential feature of the circadian timing system, a key contributor to metabolic health. However, no previous studies have investigated light-activity alignment in relation to glycemic control in human populations. RESEARCH DESIGN AND METHODS: The analysis included ∼7,000 adults (age 20-80 years) from the National Health and Nutrition Examination Survey (2011-2014) with actigraphy-measured, multiday, 24-h activity and light data...
September 21, 2023: Diabetes Care
Eric Renard, Michael Joubert, Orianne Villard, Bleuenn Dreves, Yves Reznik, Anne Farret, Jerome Place, Marc D Breton, Boris P Kovatchev
OBJECTIVE: Assess the safety and efficacy of automated insulin delivery (AID) in adults with type 1 diabetes (T1D) at high risk for hypoglycemia. RESEARCH DESIGN AND METHODS: Participants were 72 adults with T1D who used an insulin pump with Clarke Hypoglycemia Perception Awareness scale score >3 and/or had severe hypoglycemia during the previous 6 months confirmed by time below range (TBR; defined as sensor glucose [SG] reading <70 mg/dL) of at least 5% during 2 weeks of blinded continuous glucose monitoring (CGM)...
September 20, 2023: Diabetes Care
Theodora Benedek, Viktoria Wieske, Bálint Szilveszter, Klaus F Kofoed, Patrick Donnelly, José Rodriguez-Palomares, Andrejs Erglis, Josef Veselka, Gintarė Šakalytė, Nada Čemerlić Ađić, Matthias Gutberlet, Ignacio Diez, Gershan Davis, Elke Zimmermann, Cezary Kępka, Radosav Vidakovic, Marco Francone, Małgorzata Ilnicka-Suckiel, Fabian Plank, Juhani Knuuti, Rita Faria, Stephen Schröder, Colin Berry, Luca Saba, Balazs Ruzsics, Nina Rieckmann, Christine Kubiak, Kristian Schultz Hansen, Jacqueline Müller-Nordhorn, Bela Merkely, Per E Sigvardsen, Imre Benedek, Clare Orr, Filipa Xavier Valente, Ligita Zvaigzne, Martin Horváth, Antanas Jankauskas, Filip Ađić, Michael Woinke, Niall Mulvihill, Iñigo Lecumberri, Erica Thwaite, Michael Laule, Mariusz Kruk, Milica Stefanovic, Massimo Mancone, Donata Kuśmierz, Gudrun Feuchtner, Mikko Pietilä, Vasco Gama Ribeiro, Tanja Drosch, Christian Delles, Marco Melis, Michael Fisher, Melinda Boussoussou, Charlotte Kragelund, Rosca Aurelian, Stephanie Kelly, Bruno Garcia Del Blanco, Ainhoa Rubio, Mihály Károlyi, Jens D Hove, Ioana Rodean, Susan Regan, Hug Cuéllar Calabria, László Gellér, Linnea Larsen, Roxana Hodas, Adriane E Napp, Robert Haase, Sarah Feger, Mahmoud Mohamed, Lina M Serna-Higuita, Konrad Neumann, Henryk Dreger, Matthias Rief, John Danesh, Melanie Estrella, Maria Bosserdt, Peter Martus, Jonathan D Dodd, Marc Dewey
OBJECTIVE: To compare cardiac computed tomography (CT) with invasive coronary angiography (ICA) as the initial strategy in patients with diabetes and stable chest pain. RESEARCH DESIGN AND METHODS: This prespecified analysis of the multicenter DISCHARGE trial in 16 European countries was performed in patients with stable chest pain and intermediate pretest probability of coronary artery disease. The primary end point was a major adverse cardiac event (MACE) (cardiovascular death, nonfatal myocardial infarction, or stroke), and the secondary end point was expanded MACE (including transient ischemic attacks and major procedure-related complications)...
September 19, 2023: Diabetes Care
Ana Devesa, Valentin Fuster, Ravi Vazirani, Inés García-Lunar, Belén Oliva, Samuel España, Andrea Moreno-Arciniegas, Javier Sanz, Cristina Perez-Herreras, Héctor Bueno, Enrique Lara-Pezzi, Ana García-Alvarez, Vicente Martínez de Vega, Leticia Fernández-Friera, Maria G Trivieri, Antonio Fernández-Ortiz, Xavier Rossello, Javier Sanchez-Gonzalez, Borja Ibanez
OBJECTIVE: Experimental evidence suggests that metabolic syndrome (MetS) is associated with changes in cardiac metabolism. Whether this association occurs in humans is unknown. RESEARCH DESIGN AND METHODS: 821 asymptomatic individuals from the Progression of Early Subclinical Atherosclerosis (PESA) study (50.6 [46.9-53.6] years, 83.7% male) underwent two whole-body 18F-fluorodeoxyglucose positron emission tomography-magnetic resonance (18F-FDG PET-MR) 4.8 ± 0...
September 15, 2023: Diabetes Care
Dennis I Narcisse, Hwasoon Kim, Lisa M Wruck, Amanda L Stebbins, Daniel Muñoz, Sunil Kripalani, Mark B Effron, Kamal Gupta, R David Anderson, Sandeep K Jain, Saket Girotra, Jeff Whittle, Catherine P Benziger, Peter Farrehi, Li Zhou, Tamar S Polonsky, Faraz S Ahmad, Matthew T Roe, Russell L Rothman, Robert A Harrington, Adrian F Hernandez, W Schuyler Jones
OBJECTIVE: Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS: ADAPTABLE, an open-label, pragmatic study, randomized patients with stable, chronic ASCVD to 81 mg or 325 mg of daily aspirin. The effects of aspirin dosing was assessed on the primary effectiveness outcome, a composite of all-cause death, hospitalization for myocardial infarction, or hospitalization for stroke, and the primary safety outcome of hospitalization for major bleeding...
September 15, 2023: Diabetes Care
Lindsay S Mayberry, Shilin Zhao, McKenzie K Roddy, Andrew J Spieker, Cynthia A Berg, Lyndsay A Nelson, Robert A Greevy
OBJECTIVE: We validated longitudinally a typology of diabetes-specific family functioning (named Collaborative and Helpful, Satisfied with Low Involvement, Want More Involvement, and Critically Involved) in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted k-means cluster analyses with nine dimensions to determine if the typology replicated in a diverse sample and if type assignment was robust to variations in sampling and included dimensions...
September 14, 2023: Diabetes Care
Ingrid Libman, Polly J Bingley, Dorothy Becker, Jane H Buckner, Linda A DiMeglio, Stephen E Gitelman, Carla Greenbaum, Michael J Haller, Heba M Ismail, Jeffrey Krischer, Wayne V Moore, Antoinette Moran, Andrew B Muir, Vana Raman, Andrea K Steck, Frederico G S Toledo, John Wentworth, Diane Wherrett, Perrin White, Lu You, Kevan C Herold
OBJECTIVE: Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 individuals with stage 1 T1D to treatment with hydroxychloroquine (n = 183; 5 mg/kg per day to a maximum of 400 mg) or placebo (n = 90) and assessed whether hydroxychloroquine treatment delayed or prevented progression to stage 2 T1D (i...
September 14, 2023: Diabetes Care
Mille Baekdal, Sophie W Nielsen, Carsten P Hansen, Jan H Storkholm, Gerrit van Hall, Bolette Hartmann, Jens J Holst, Tina Vilsbøll, Asger Lund, Filip K Knop
OBJECTIVE: Insulin remains the only glucose-lowering treatment modality recommended for totally pancreatectomized patients. We investigated the effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on fasting and postprandial glucose concentrations in pancreatectomized patients and matched healthy control participants. RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled crossover study, 10 pancreatectomized patients and 10 matched control participants underwent two 3-h liquid mixed meal tests preceded by two doses of 25 mg empagliflozin (administered the night before and in the morning of the meal test) or placebo, respectively...
September 13, 2023: Diabetes Care
Jasaman Tojjar, Matti Cervin, Emma Hedlund, Qefsere Brahimi, Gun Forsander, Helena Elding Larsson, Johnny Ludvigsson, Ulf Samuelsson, Claude Marcus, Martina Persson, Annelie Carlsson
OBJECTIVE: To examine sex differences in children with newly diagnosed type 1 diabetes (T1D) with respect to age at diagnosis, presence of autoantibodies (GAD antibody [GADA], insulinoma-associated protein 2 [IA-2A], insulin autoantibody [IAA], and zinc transporter 8 autoantibody), and HLA risk. RESEARCH DESIGN AND METHODS: A population-based nationwide sample of 3,645 Swedish children at T1D diagnosis was used. RESULTS: Girls were younger at T1D diagnosis (9...
September 12, 2023: Diabetes Care
Alexander Kutz, Dae Hyun Kim, Deborah J Wexler, Jun Liu, Sebastian Schneeweiss, Robert J Glynn, Elisabetta Patorno
OBJECTIVE: To evaluate the comparative cardiovascular effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase 4 inhibitors (DPP-4is) in older adults with type 2 diabetes (T2D) across different frailty strata. RESEARCH DESIGN AND METHODS: We performed three 1:1 propensity score-matched cohort studies, each stratified by three frailty strata, using data from Medicare beneficiaries (2013-2019) with T2D who initiated SGLT-2is, GLP-1RAs, or DPP-4is...
September 7, 2023: Diabetes Care
Holly K O'Donnell, Cristy Geno Rasmussen, Fran Dong, Kimber M Simmons, Andrea K Steck, Brigitte I Frohnert, Kimberly Bautista, Marian J Rewers, Judith Baxter
OBJECTIVE: To assess anxiety and risk perception among parents whose children screened positive for islet autoantibodies, indicating elevated risk for type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The Autoimmunity Screening for Kids (ASK) study identified 319 children age 1 to 17 years at risk for T1D via screening for islet autoantibodies; 280 children with confirmed islet autoantibodies and their caregivers enrolled in a follow-up education and monitoring program to prevent diabetic ketoacidosis at diagnosis...
September 6, 2023: Diabetes Care
Julio Rosenstock, Luis Vázquez, Stefano Del Prato, Denise Reis Franco, Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K Bergman, Angel Rodríguez
OBJECTIVE: Tirzepatide is a novel single-molecule glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, which demonstrated unprecedented improvements in glycemic control and body weight reduction, in the SURPASS phase 3 program. In this exploratory analysis, we aimed to characterize tirzepatide-treated participants who achieved HbA1c <5.7% and evaluate changes in clinical markers associated with long-term cardiometabolic health. RESEARCH DESIGN AND METHODS: Baseline characteristics and change from baseline to week 40 for several efficacy and safety parameters were analyzed according to HbA1c attainment category (<5...
September 6, 2023: Diabetes Care
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.